Journey Medical director granted 10,000 RSUs

ROSENWALD LINDSAY A MD reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

ROSENWALD LINDSAY A MD reported acquisition or exercise transactions in this Form 4 filing.

Journey Medical Corp director Lindsay A. Rosenwald, M.D. reported an equity compensation award rather than an open-market trade. On June 25, 2026, he was granted 10,000 restricted stock units that are scheduled to vest as 10,000 shares on June 25, 2027.

After this award, his direct holdings of common stock, including restricted stock units that vest over various periods, total 221,146 shares. A separate entry shows 176,470 shares held indirectly through a limited liability company over which he, as managing member, is deemed to have voting and investment power.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 2 txns

Insider ROSENWALD LINDSAY A MD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.0001 par value	10,000	$0.00	$0.00
holding	Common Stock, $0.0001 par value	--	--	--

Holdings After Transaction: Common Stock, $0.0001 par value — 221,146 shares (Direct); Common Stock, $0.0001 par value — 176,470 shares (Indirect, See Footnote)

Footnotes (3)

1. F1. On June 25, 2026, the reporting person was granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 10,000 shares on June 25, 2027.
2. F2. Includes restricted stock units, which vest over various time periods.
3. F3. The shares are held by a limited liability company over which the reporting person, as managing member, is deemed to have voting and investment power.

Key Figures

RSU grant: 10,000 units Grant price: $0.0000 per share Vesting date: June 25, 2027 +2 more

5 metrics

RSU grant 10,000 units Restricted stock units granted on June 25, 2026

Grant price $0.0000 per share Price per share for RSU award

Vesting date June 25, 2027 All 10,000 RSUs vest into shares on this date

Direct holdings after grant 221,146 shares Common stock directly held after June 25, 2026 award

Indirect holdings via LLC 176,470 shares Shares held by LLC with Rosenwald deemed to have voting and investment power

Key Terms

restricted stock units, 2015 Stock Plan, vesting, voting and investment power, +1 more

5 terms

restricted stock units financial

"the reporting person was granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2015 Stock Plan financial

"granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended"

vesting financial

"which will vest in accordance with the following schedule: 10,000 shares on June 25, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

voting and investment power financial

"the reporting person, as managing member, is deemed to have voting and investment power"

indirect ownership financial

"The shares are held by a limited liability company over which the reporting person ... is deemed to have voting and investment power"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Journey Medical (DERM) report for Lindsay A. Rosenwald on June 25, 2026?

Journey Medical reported that director Lindsay A. Rosenwald, M.D. received an equity grant of 10,000 restricted stock units on June 25, 2026. The award was issued at a price of $0.0000 per share as compensation, not an open-market stock purchase or sale.

How many Journey Medical (DERM) shares did Lindsay A. Rosenwald hold directly after this Form 4 filing?

Following the June 25, 2026 award, Lindsay A. Rosenwald, M.D. directly held 221,146 shares of Journey Medical common stock. This figure includes restricted stock units that vest over various time periods, as disclosed in the filing’s footnotes and transaction details.

When do Lindsay A. Rosenwald’s new restricted stock units in Journey Medical (DERM) vest?

The 10,000 restricted stock units granted to Lindsay A. Rosenwald, M.D. on June 25, 2026 are scheduled to vest as 10,000 shares on June 25, 2027. Vesting is governed by Journey Medical’s 2015 Stock Plan, as amended, according to the filing footnote.

Was the Journey Medical (DERM) Form 4 for Lindsay A. Rosenwald an open-market stock purchase or sale?

No, the reported activity is a grant of 10,000 restricted stock units at $0.0000 per share as compensation. The Form 4 does not show any open-market purchases or sales; it records an award under Journey Medical’s 2015 Stock Plan, as amended.

What indirect Journey Medical (DERM) holdings were reported for Lindsay A. Rosenwald on this Form 4?

The filing lists 176,470 shares of Journey Medical common stock held indirectly through a limited liability company. Lindsay A. Rosenwald, M.D., as the managing member of that LLC, is deemed to have voting and investment power over these indirectly held shares.

Under which plan were Lindsay A. Rosenwald’s new Journey Medical (DERM) restricted stock units granted?

The 10,000 restricted stock units granted on June 25, 2026 were issued under Journey Medical’s 2015 Stock Plan, as amended. This plan governs the terms and vesting schedule, including the vesting of all 10,000 shares on June 25, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 04:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROSENWALD LINDSAY A MD

(Last) (First) (Middle)

C/O JOURNEY MEDICAL CORPORATION

9237 E VIA DE VENTURA BLVD., SUITE 105

(Street)

SCOTTSDALE ARIZONA 85258

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Journey Medical Corp [ DERM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.0001 par value	06/25/2026		A		10,000(1)	A	$0	221,146(2)	D
Common Stock, $0.0001 par value								176,470	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On June 25, 2026, the reporting person was granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 10,000 shares on June 25, 2027.

2. Includes restricted stock units, which vest over various time periods.

3. The shares are held by a limited liability company over which the reporting person, as managing member, is deemed to have voting and investment power.

	/s/ Ramsey Alloush, attorney-in-fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)